ESMO: Merck touts Keytruda’s breast cancer survival win as first-to-market Tecentriq leaves the ringnews2021-09-18T08:57:54+00:00September 18th, 2021|Fierce Pharma|
FDA advisors reject Pfizer COVID-19 boosters for all, but agree to shots for elderly and high risknews2021-09-17T21:32:06+00:00September 17th, 2021|Fierce Pharma|
FDA advisers reject Pfizer COVID-19 boosters for all, but agree to shots for elderly and high risknews2021-09-17T21:32:06+00:00September 17th, 2021|Fierce Pharma|
Horizon partners with MIT for crowdsourced rare disease solutions, narrows to 5 finalistsnews2021-09-17T19:02:11+00:00September 17th, 2021|Fierce Pharma|
ESMO: Studies show COVID vaccines effective and safe for cancer patients, but jury still out for one key groupnews2021-09-17T18:29:36+00:00September 17th, 2021|Fierce Pharma|
ESMO: With massive tumor progression edge, AstraZeneca-Daiichi’s Enhertu shows Roche’s Kadcyla who’s the better breast cancer drugnews2021-09-17T17:37:47+00:00September 17th, 2021|Fierce Pharma|
Gilead’s slumping COVID-19 drug takes another hit with study showing no real benefitnews2021-09-17T15:06:22+00:00September 17th, 2021|Fierce Pharma|
ESMO: In landmark win, Novartis’ Kisqali extends breast cancer survival by one year. Can it challenge Pfizer’s Ibrance?news2021-09-17T14:34:47+00:00September 17th, 2021|Fierce Pharma|
ESMO: Pfizer, Astellas’ latest Xtandi survival data may shore up prostate cancer lead over J&Jnews2021-09-17T12:23:58+00:00September 17th, 2021|Fierce Pharma|
With new facility and leadership, CDMO Genezen is stepping up to the big leaguesnews2021-09-17T11:40:40+00:00September 17th, 2021|Fierce Pharma|
